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対訳 
Salubrinalと guanabenzは、eukaryotic translation initiation factor 2 alpha (eIF2α)の脱リン酸化
阻害剤として知られていて、それらは、破骨細胞分化のマスター分子である nuclear factor of 
activated T-cells, cytoplasmic 1 (NFATc1)を低下させ、破骨細胞分化を抑制する。NFATc1の抑
制メカニズムはあまり解明されていない。そこで、ゲノムワイドのマイクロアレー解析を用いて、私たちは、
特に salubrinalおよび guanabenzが作用する破骨細胞分化に関与する分子レギュレーターを研究し
た。私たちは、2つの遺伝子群を同定した。1つは、receptor activator of nuclear factor kappa-B 
ligand (RANKL)によって亢進され、salubrinalおよび guanabenzによって抑制される遺伝子群。もう
1つは、RANKLによって抑制され、salubrinalおよび guanabenzによって亢進される遺伝子群。マイ
クロアレーおよび qPCRの結果により、zinc finger protein, FYVE domain containing 21 (Zfyve21)
と DNA-damage-inducible transcript 4 (Ddit4)が、RANKLによって抑制され、salubrinalおよび
guanabenzによって亢進されることが明らかになった。また、Zfyve21あるいは Ddit4の部分的なサイレ
ンシングが salubrinalおよび guanabenzによる NFATc1の抑制を軽減させた。総括すると、この研究
により Zfyve21および Ddit4が破骨細胞分化の阻害分子であることが明らかになった。このことより、
私たちは、それらが骨粗鬆症などの骨疾患から生じる骨量低下を抑制する新規標的分子になりうる
ことを期待する。 
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Abstract 
Salubrinal and guanabenz are two known inhibitors of de-phosphorylation of eukaryotic 
translation initiation factor 2 alpha (eIF2α), and they suppress osteoclastogenesis through 
downregulating nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), a master molecule 
of osteoclastogenesis.  The mechanism of NFATc1 suppression is not well understood. Using 
genome-wide microarray analysis, we investigated molecular regulators of osteoclastogenesis, in 
particular, in response to salubrinal and guanabenz.  We identified two sets of genes: a set of 
genes that were upregulated by receptor activator of nuclear factor kappa-B ligand (RANKL) 
and downregulated by salubrinal and guanabenz; and the other set of genes that were 
downregulated by RANKL and upregulated by salubrinal and guanabenz. The microarray and 
qPCR result revealed that a zinc finger protein, FYVE domain containing 21 (Zfyve21), as well 
as DNA-damage-inducible transcript 4 (Ddit4), were suppressed by RANKL and upregulated by 
salubrinal and guanabenz. A partial silencing of Zfyve21 or Ddit4 attenuated salubrinal- and 
guanabenz-driven suppression of NFATc1. Collectively, this study demonstrates that Zfyve21 
and Ddit4 are two inhibitors of osteoclastogenesis.  We expect that they may potentially serve as 
novel targets for preventing bone loss from skeletal diseases such as osteoporosis.      
 
Key words： osteoclasts, Zfyve21, Ddit4, salubrinal, guanabenz 
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 Introduction 
Stress to the endoplasmic reticulum (ER) is induced by a multitude of causes, including UV, 
viral infection, and protein misfolding1, 2).  The ER stress is known to generate an integrated 
stress response (ISR), in which the general rate of protein synthesis is reduced by elevating the 
phosphorylation level of eukaryotic translation initiation factor 2 alpha (eIF2α)3).  Severe ER 
stress leads to cellular apoptosis, and the progression of various diseases are reported to be linked 
to the ER stress and regulation of eIF2α phosphorylation4- 6).  Salubrinal and guanabenz are 
small synthetic agents, which bind to a protein phosphate 1 (PP1) complex and inhibit de-
phosphorylation of eIF2α7, 8). It has been shown in pre-clinical studies that their administration 
improves varying symptoms of diseases such as neuronal disorders, inflammatory diseases, and 
cancer, primarily via alleviating detrimental effects caused by the ER stress9-14). 
 
Regarding skeletal diseases, salubrinal and guanabenz are reported to present multiple beneficial 
effects11, 15-20). First, they stimulate differentiation of bone-forming osteoblasts, through the 
upregulation of activating transcription factor 4 (ATF4) and osteocalcin16). Second, they 
attenuate differentiation of bone-resorbing osteoclasts, through downregulating nuclear factor of 
activated T-cells, cytoplasmic 1 (NFATc1)17, 18). Third, salubrinal presents chondroprotective 
effects by suppressing inflammatory cytokines and matrix metalloproteinase 13 (MMP13)19, 20). 
Lastly, salubrinal improves inflammatory symptoms of anti-collagen antibody-induced arthritis 
via suppression of dual-specificity phosphatase 2 (Dusp2)11).    
 
In this study, we conducted genome-wide expression analysis using RAW264.7 pre-osteoclast 
cells and investigated a regulatory mechanism that is involved in salubrinal- and guanabenz-
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driven suppression of NFATc1.  This microarray analysis led us to focus on two potential 
regulators: a zinc finger protein, FYVE domain containing 21 (Zfyve21), and DNA-damage-
inducible transcript 4 (Ddit4).  Both were suppressed by receptor activator of nuclear factor 
kappa-B ligand (RANKL), while upregulated by salubrinal and guanabenz. To evaluate the 
involvement of Zfyve21 and Ddit4 in expression of NFATc1, we employed RNA interference 
with specific siRNAs.  Herein, we demonstrate the novel role of Zfyve21 and Ddit4 in RANKL-
induced regulation of NFATc1.     
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Materials and Methods 
Cell Culture 
RAW264.7 mouse pre-osteoclast cells were cultured in αMEM containing 10% fetal bovine 
serum and antibiotics (50 units/ml penicillin and 50 µg/ml streptomycin; Life Technologies, 
Grand Island, NY, USA).  Cells were maintained at 37°C and 5% CO2 in a humidified incubator.  
Osteoclastogenesis and TRAP (Tartrate-resistant acid phosphatase) staining 
RAW264.7 cells were plated at 2.0 x 104 and 1.0 x 105 cells into a 12-well and 60 mm dish, 
respectively, and cultured with 20 or 50 ng/ml RANKL (PeproTech, Rocky Hills, NC, USA) in 
the presence and absence of 10 or 20 µM salubrinal or guanabenz (R&D Systems, Minneapolis, 
MN, USA)16).  After 5-day incubation with RANKL, cells were treated for TRAP staining using 
an acid phosphatase leukocyte kit (Sigma, St. Louise, MO, USA). The number of TRAP-positive 
cells containing three or more nuclei was determined.   
Quantitative real-time PCR 
Total RNA was extracted using an RNeasy Plus mini kit (Qiagen, Germantown, MD, USA).  
Reverse transcription was conducted with a high capacity cDNA reverse transcription kit 
(Applied Biosystems, Carlsbad, CA, USA), and quantitative real-time PCR (qPCR) was 
performed using ABI 7500 with Power SYBR green PCR master mix kits (Applied Biosystems).  
We evaluated mRNA levels of TRAP, cathepsin K, Dscr1, Dusp2, Hipk2, Ptpn22, Tnip1, Agap1, 
Ddit4, Pla2g15, Ttf2, and Zfyve21 with the PCR primers listed in Table 1. GAPDH was used for 
an internal control. 
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Western blot analysis 
Cells were lysed in a radioimmuno-precipitation assay (RIPA) buffer containing protease 
inhibitors (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and phosphatase inhibitors 
(Calbiochem, Billerica, MA, USA). Isolated proteins were fractionated using 10% SDS gels and 
electro-transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). The membrane 
was incubated with primary antibodies followed by goat anti-mouse IgG conjugated with 
horseradish peroxidase (Cell Signaling, Danvers, MA, USA). We used antibodies against 
NFATc1 (Santa Cruz) and β-actin (Sigma). The level of proteins was detected using a 
SuperSignal west femto maximum sensitivity substrate (Thermo Scientific, Waltham, MA, 
USA). 
Microarray analysis 
A microarray experiment was conducted using RAW264.7 cells. We employed 4 groups (3 
samples per group; Illumina MouseWG-6 v2.0): CN (control), RANKL (20 ng/ml RANKL), Sal 
(20 ng/ml RANKL with 20 µM salubrinal), and Gu (20 ng/ml RANKL with 20 µM guanabenz).  
Cells were harvested 4 h after treatment with the above agents.   Genes that were differentially 
expressed after addition of salubrinal and guanabenz were identified by calculating fold change. 
Note that all of the chosen genes had raw signal values greater than 100. Of particular interest 
were the genes that were upregulated by addition of RANKL and downregulated by addition of 
salubrinal and guanabenz, and the genes that were downregulated by addition of RANKL and 
upregulated by addition of salubrinal and guanabenz.  Statistical significance of the regulation 
was assessed by Student’s t-test. 
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Knockdown of NFATc1, Dscr1, Ptpn22, Zfyve21, and Ddit4 by siRNA 
RAW264.7 cells were treated with siRNA specific to NFATc1 (5’-CGG UUA CUU GGA GAA 
UGA A- 3’; Life Technologies), Dscr1 (5’-CGU CAU AAA UUA CGA UCU U-3’; Life 
Technologies), Ptpn22 (5’-GUU UGA AGA UUU UUC GAA A-3’; Life Technologies), 
Zfyve21 (5’-AGG CGG AGU UUU AUG ACA A-3’; Life Technologies), Ddit4 (5’-GCU AAG 
UAC CGG CUU CAG A- 3’; Life Technologies), or a nonspecific control (NC) (5’-UGU ACU 
GCU UAC GAU UCG G-3’, Life Technologies).  Cells were transiently transfected with siRNA 
in Opti-MEM I medium with Lipofectamine RNAiMAX (Life Technologies).  The efficiency of 
RNA silencing was assessed with immunoblotting or qPCR 48 h after transfection. 
Statistical analysis 
Three or four independent in vitro experiments were conducted, and data were expressed as 
mean ± S.D.  For comparison among multiple samples, statistical significance was evaluated at p 
< 0.05.  The single and double asterisks indicate p < 0.05 and p < 0.01, respectively.  
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Results 
Suppression of osteoclastogenesis by salubrinal and guanabenz 
The number of TRAP-positive multinucleated osteoclasts was significantly reduced by 10 or 20 
µM salubrinal and guanabenz in RAW264.7 cells (Fig. 1A & 1B). The level of RANKL-driven 
NFATc1 protein was also significantly attenuated by salubrinal and guanabenz (Fig. 2A & 2B).  
A partial silencing of NFATc1 by its siRNA suppressed the mRNA levels of TRAP and 
cathepsin K compared to those treated with non-specific control (NC) siRNA (Fig. 2C & 2D). 
The reduction ratio of the mRNA levels of TRAP and cathepsin K was higher than that of 
NFATc1 mRNA. This difference might be caused by time dependent peak/bottom expression 
levels among NFATc1, TRAP, and cathepsin K.   
Microarray data analysis in response to salubrinal/guanabenz  
We identified two sets of genes (the first set of genes that were upregulated by RANKL but 
downregulated by salubrinal and guanabenz; and the second set of genes that were 
downregulated by RANKL but upregulated by salubrinal and guanabenz).  Five genes were 
chosen for each set (Table 2 & 3).  The first set of genes such as Dscr1, Dusp2, Hipk2, Ptpn22, 
and Tnip1 were upregulated by RANKL, while the second set of genes such as Agap1, Ddit4, 
Pla2g15, Ttf2, and Zfyve21 were downregulated by RANKL.  In qPCR, four genes (Dscr1, 
Ptpn22, Ddit4, and Zfyve21) were confirmed to follow the same trend to the microarray result 
(Fig. 3A & 3B).  Hereafter, we focused on the role of Dscr1, ptpn22, Zfyve21, and Ddit4. 
Effects of Dscr1, Ptpn22, Zfyve21 and Ddit4 on NFATc1 
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In order to examine the role of Dscr1, Ptpn22, Zfyve21 and Ddit4 in regulation of RANKL-
driven NFATc1, we employed RNA interference using siRNA specific for Dscr1, Ptpn22, 
Zfyve21 or Ddit4 (Fig. 4). RAW264.7 cells, transfected with NC siRNA, showed a reduction of 
NFATc1 in response to salubrinal and guanabenz.  A partial silencing of Dscr1 and Ptpn22 did 
not affect expression of RNAKL-induced NFATc1 (Fig. 4B & 4D). However, a partial silencing 
of Zfyve21 and Ddit4 attenuated salubrinal/guanabenz-driven suppression of NFATc1 (Fig. 4F 
& 4H).   
11 
Discussion 
We present in this study that salubrinal and guanabenz, which inhibit de-phosphorylation of 
eIF2α and attenuate the ER stress, suppress osteoclastogenesis via downregulating NFATc1.  
The genome-wide mRNA profiling using RAW264.7 cells reveals that Zfyve21 and Ddit4 are 
downregulated by RANKL and this downregulation is suppressed by salubrinal/guanabenz.  The 
expression patterns of Zfyve21 and Ddit4 in response to RANKL and salubrinal/guanabenz were 
verified by qPCR, and the involvement of Zfyve21 and Ddit4 in expression of NFATc1 was 
validated using RNA interference.  
Microarray analysis followed by qPCR verification indicates that four genes are responsive to 
salubrinal and guanabenz and potentially novel regulators of osteoclastogenesis.  RANKL 
elevates the mRNA levels of Dscr1 and Ptpn22 and their elevation is suppressed by salubrinal 
and guanabenz, while the mRNA levels of Zfyve21 and Ddit4 are downregulated by RANKL 
and its downregulation is upregulated by salubrinal and guanabenz.  A partial silencing of Dscr1 
and Ptpn22 revealed that they do not significantly alter expression of NFATc1. Therefore, in this 
study, we focused on the role of Zfyve21 and Ddit4 as potential inhibitors of osteoclastogenesis. 
Zfyve21 is a member of a protein family that consists of a phosphatidylinositol 3-phosphate-
binding FYVE domain21).  This gene is reported to be involved in cell migration and cancer 
metastasis via disassembling focal adhesions21, 22).  It is possible that Zfyve21 is inhibitory in a 
process of multi-nucleation of osteoclasts, but further analysis is necessary to understand its role 
in osteoclastogenesis. Ddit4 is a transcriptional target of p63 and p53, as well as a hypoxia-
inducible factor 1-responsive gene23, 24).  It is reported that transcription of Ddit4 is stimulated by 
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ATF4 that is upregulated by the elevated phosphorylation of eIF2α 25).  Ddit4 regulates 
mTORC1 signaling, and its expression level is upregulated during pathological conditions such 
as hypoxia, cancer cachexia, and diabetes26).  Since salubrinal and guanabenz elevate the 
phosphorylation level of eIF2α, our result with Ddit4 is consistent with the role of eIF2α in 
osteoclast development.  
It has been reported that salubrinal and guanabenz induce cell apoptosis in cancer cells13, 14). For 
instance, apoptosis is induced in breast cancer cells by salubrinal or guanabenz at a dose above 
20 µM 13).  Salubrinal and guanabenz at a dose below 20 µM, however, are not linked to cell 
mortality in RAW264.7 cells16). Therefore, it is unlikely that Zfyve21 and Ddit4 are directly 
involved in cell mortality.    
Both salubrinal and guanabenz are known to reduce the ER stress and inhibit de-phosphorylation 
of eIF2α7, 8). However, there are differences in their functions.  In pre-clinical studies, salubrinal 
and not guanabenz reduces MMP13 activity via reducing the phosphorylation level of NFκB, 
and attenuates the progression of osteoarthritis19, 20).  On the other hand, guanabenz and not 
salubrinal is known as an agonist of α2 adrenergic receptor and is used for treatment of 
hypertension27).  The common feature of salubrinal and guanabenz is their interactions with PP1 
subunits, while the different feature is their unique binding partners in PP1 complex7, 8).    
In this study, we specifically analyzed the involvement of Zfyve21 and Ddit4 in regulation of 
NFATc1 from a list of ten genes in Table 2 & 3.  Further analysis is recommended to evaluate 
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Zfyve21’s and Ddit4’s actions, using primary macrophages and animal models.  In summary, 
Zfyve21 and Ddit4 are identified as two novel regulators that inhibit expression of NFATc1 and 
suppress osteoclastogenesis.  We expect that this study contributes to our basic understanding of 
osteoclastogenesis and development of a new therapeutic target for bone diseases such as 
osteoporosis. 
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Figure Legends 
Figure 1. Inhibitory effects of salubrinal and guanabenz on development of osteoclasts in the 
presence of 20 ng/ml RANKL.  Sal = salubrinal, and Gu = guanabenz. (A&B) Suppression of 
TRAP-positive multinucleated osteoclasts by 10 or 20 µM salubrinal and guanabenz in 
RAW264.7 cells, respectively. 
Figure 2. Suppression of RANKL-driven osteoclast-linked genes in response to 
salubrinal/guanabenz in RAW264.7 cells. Sal = 20 µM salubrinal, and Gu = 20 µM guanabenz. 
(A) Salubrinal induced inhibition of NFATc1 on day 2 in RAW264.7 cells. (B) Guanabenz 
induced inhibition of NFATc1 on day 2 in RAW264.7 cells. (C) Partial knockdown of NFATc1 
in the presence and absence of RANKL in RAW264.7 cells. (D) Levels of TRAP and cathepsin 
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K mRNAs in response to non-specific control (NC) siRNA and NFATc1 siRNA. The double 
asterisks indicate p < 0.01.  Note that 20 and 50 ng/ml RANKL was used in (A&B) and (C&D), 
respectively.  
Figure 3.  Prediction of molecular regulators in osteoclastogenesis.  (A) Potential activators of 
NFATc1, suppressible by 20 µM salubrinal/guanabenz. (B) Potential inhibitors of NFATc1, 
inducible by 20 µM salubrinal/guanabenz. Note that 20 ng/ml RANKL was used. 
Figure 4. Salubrinal- and guanabenz-driven upregulation in Zfyve21 and Ddit4.  (A&B) 
Undetectable effect of Dscr1 siRNA on NFATc1.  (C&D) Undetectable effect of Ptpn22 siRNA 
on NFATc1.  (E) Zfyve21 mRNA level after transfecting siRNA specific to Zfyve21. (F) 
NFATc1 protein level in the presence and absence of 20 µΜ salubrinal/guanabenz in response to 
Zfyve21 siRNA treatment. (G) Ddit4 mRNA level after transfecting siRNA specific to Ddit4. 
(H) NFATc1 protein level in the presence and absence of 20 µM salubrinal/guanabenz in 
response to Ddit4 siRNA treatment. The double asterisks indicate p < 0.01. Note that 20 ng/ml 
RANKL was used in (B, D, F, and H). 
Figure 5. Proposed mechanism of salubrinal and guanabenz’ action on osteoclastogenesis. 
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Table 
Table 1. Real-time PCR primers used in this study. 
target forward primer backward primer 
TRAP 5’-TCCTGGCTCAAAAAGCAGTT-3’ 5’-ACATAGCCCACACCGTTCTC-3’ 
cathepsin K 5’-CAGCTTCCCCAAGATGTGAT-3’ 5’-AGCACCAACGAGAGGAGAAA-3’ 
Dscr1 5’-CCCGACAAACAGTTCCTCAT-3’ 5’-CACACTGGGAGTGGTGTCTG-3’ 
Dusp2 5’-TGGAAATCTTGCCCTACCTG-3’ 5’-CTCCTGGAACCAGGCACTTA-3’ 
Hipk2 5’-CTTCCAGCACAAGAACCACA-3’ 5’-ACCTTCACTCGGTACGGTTG-3’ 
Ptpn22 5’-ATAGCAACCCACACGACTCC-3’ 5’-TGCTCCAAATGTTACCACCA-3’ 
Tnip1 5’-AAGAGGAGGAGAAGGCCAAG-3’ 5’-CCTTGTAGGCATGGTGAGGT-3’ 
Agap1 5’-CGAAGATGCTTTCGTGAACA-3’ 5’-CCCTTCATCCCTAATCAGCA-3’ 
Ddit4 5’-CTCTGGGATCGTTTCTCGTC-3’ 5’-GACACCCCATCCAGGTATGA-3’ 
Pla2g15 5’-TGCTTGTATGGCACTGGTGT-3’ 5’-TCCAGAAGCACACGTTTCAG-3’ 
Ttf2 5’-GCCCAAAACTGAGAAAGCTG-3’ 5’-ACCAAAAGCTGGGTTTCCTT-3’ 
Zfyve21 5’-GGGGACAGTCATCGTGAAAT-3’ 5’-AGCTTGGTAGCCTTGTGCAT-3’ 
GAPDH 5’-TGCACCACCAACTGCTTAG-3’ 5’-GGATGCAGGGATGATGTTC-3’ 
Table 2. Genes upregulated by RANKL and downregulated by salubrinal/guanabenz. 
 
Table 3. Genes downregulated by RANKL and upregulated by salubrinal/guanabenz. 
Gene symbol Fold Change 
[G/R] 
P value 
[G/R] 
Fold Change 
[S/R] 
P value 
[S/R] 
Fold Change 
[R/C] 
P value 
[R/C] 
Agap1 1.57 3.01E-04 1.19 1.62E-02 -1.72 1.96E-02 
Ddit4 1.10 1.91E-02 1.22 1.70E-03 -1.39 2.10E-03 
Pla2g15 1.64 1.33E-03 1.17 4.00E-02 -1.80 1.45E-04 
Ttf2 1.42 1.15E-02 1.20 3.42E-02 -1.59 1.44E-03 
Zfyve21 1.36 2.38E-03 1.25 6.38E-03 -1.52 2.66E-03 
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P value 
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Dscr1 -1.53 8.11E-06 -1.24 1.18E-03 1.91 2.30E-07 
Dusp2 -1.62 6.87E-04 -1.33 3.73E-02 1.82 6.84E-04 
Hipk2 -1.33 2.33E-02 -1.29 2.46E-02 1.44 5.61E-03 
Ptpn22 -1.87 1.12E-04 -1.48 1.69E-02 2.11 8.07E-04 
Tnip1 -1.43 5.63E-03 -1.34 3.78E-02 2.66 9.41E-04 
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Inhibitors of eIF2α de-phosphorylation 
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